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Natural Killer (NK) cells are known to reject several experimental murine tumors, but their antineoplastic activity in
humans is not generally agreed upon, as exemplified by an interesting correspondence recently appeared in
Cancer Research. In the present commentary, we join the discussion and bring to the attention of the readers of
the Journal of Translational Medicine a set of recent, related reports. These studies demonstrate that effectors of the
adaptive and innate immunity need to actively cooperate in order to reject tumors and, conversely, tumors protect
themselves by dampening both T and NK cell responses. The recently reported ability of indoleamine 2,3-dioxygenase
(IDO) and prostaglandin E2 (PGE2) expressed by melanoma cells to down-regulate activating NK receptors is yet
another piece of evidence supporting combined and highly effective T/NK cell disabling. Major Histocompatibility
Complex class I (MHC-I) molecules, including Human Leukocyte Antigen E (HLA-E), represent another class of shared
activating/inhibitory ligands. Ongoing clinical trials with small molecules interfering with IDO and PGE2 may be
exploiting an immune bonus to control cancer. Conversely, failure to simultaneously engage effectors of both the
innate and the adaptive immunity may contribute to explain the limited clinical efficacy of T cell-only vaccination trials.
Shared (T/NK cells) natural immunosuppressants and activating/inhibitory ligands expressed by tumor cells may
provide mechanistic insight into impaired gathering and function of immune effectors at the tumor site.Commentary
A report published on March 15, and the following corres-
pondence published October 11, 2012 in Cancer Research
[1-3] revamp the old vexing question of Natural Killer
(NK) cells and tumors. Do NK cells reject human
tumors? Do they positively influence clinical outcome?
Do tumors bother at all evading NK cells? In their ori-
ginal paper, Pietra and colleagues appear to answer yes to
all these questions. They show that melanoma cells pro-
duce indoleamine 2,3-dioxygenase (IDO) and prostaglan-
din E2 (PGE2), two natural immunosuppressants that
down-regulate activating NK receptors [1]. Whereas this
is highly suggestive of an active immunoevasion strategy,
in a subsequent letter to the Editor Sconocchia et al.
emphasize the poor NK cell infiltration of most tumor
lesions, including melanoma, a finding that is suggested
to question the role of NK cells in contrasting solid
tumor progression in humans [2]. In their conclusive* Correspondence: giacomini@ifo.it
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reproduction in any medium, provided the orauthors’ reply, Pietra et al. attempt to reconcile these
views. In extreme synthesis, they argue that NK cell dis-
armament and poor infiltration may be two sides of the
same coin [3].
This interpretation is fully agreeable, but in our opin-
ion it enlightens a particular case of a more general and
widely inclusive concept. As thoroughly documented by
Shanker and Marincola in a recent review, tumor rejec-
tion is a two-way, cooperative endeavor involving both
innate and adaptive immunity: T and NK cells in the
first place, but most certainly also other immune cells,
including dendritic cells, macrophages, and neutrophils
[4]. This is particularly evident in certain murine experi-
mental tumor systems in which a direct communication
axis has been identified between T and NK cells [5,6].
Somewhat reciprocal to this concept, we recently reviewed
the available evidence that tumor immunoevasion requires
the simultaneous derangement of both T and NK cells,
as shown by the analysis of Major Histocompatibility
Complex class I (MHC-I) phenotypes of human tumors
[7]. Herein, we go on and argue that the function of a cored. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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begins to be unraveled. IDO, PGE2 and self MHC-I may
be the prototypes of shared (T/NK) immunoevasion
ligands. They may advance our understanding of how
tumors are rejected or, alternatively, tolerated by the im-
mune system on the whole, and not just T or NK cells
separately considered.
IDO and PGE2 have long been known to inhibit CD8+
T cells and increase suppressive, regulatory T cell (Treg)
responses (reviewed in [8-11] and see Figure 1). Indeed,
the combined inhibitory effect of IDO on T and NK cells
had already been elucidated in 2002, in a seminal paper
from the group led by the late GB Ferrara [12]. Expression
of IDO and PGE2 is associated with progression and/or
poor prognosis in many tumors including melanoma and
colorectal carcinoma [8,9]. In both melanoma and colorec-
tal carcinoma, IDO is detrimental to survival regardless of
whether it is measured on cancer cells in primary lesions
[13], or leukocytes (e.g. dendritic-like cells) in tumor-free
draining lymph nodes ([14] and reviewed therein).
Interestingly, the activating NK receptors inhibited by
IDO and PGE2 are functionally counteracted by NKG2A,
an inhibitory receptor utilized by both T and NK cells
(Figure 1). Like IDO and PGE2, the NKG2A inhibitory
ligand HLA-E is expressed and functional in tumor cells,
including melanoma and colorectal carcinoma ([15],













Figure 1 IDO, PGE2 and HLA-E: a core set of
immunosuppressants and immunomodulators acting on both T
and NK cells. Tumor cells create a potentially inhibitory
microenvironment by producing IDO (causing tryptophan depletion
and L-kynurenine accumulation), secreting PGE2, and expressing
surface HLA-E. IDO and PGE2 inhibit T cell functions both directly and
indirectly (through Treg cells), and down-regulate NK receptors,
although with a different spectrum of activity. HLA-E binds the
inhibitory receptor NKG2A, although it may also bind the activating
receptor NKG2C. In addition, PGE2 is known to suppress IFN-γ
production by T and NK cells, IL12/IL15 responsiveness of NK cells, and
both production of, and responsiveness to, IL2 by T cells [1,8-10,15].Figure 2A). HLA-E:NKG2A interactions are recapitulated
in vivo: NKG2A+ T cells preferentially infiltrate a sub-
group of HLA-E-high colorectal carcinomas (Figure 2B)
with favorable 5-yr disease-free and overall survival [16].
These observations strongly suggest that different tu-
mors preferentially tamper with shared T/NK cell immu-
nosuppressants and ligands, e.g. the two sides of the
immunoevasion coin are indeed poor tumor lysis and
poor lymphoid infiltration, as argued by Pietra et al. and
Sconocchia et al., but these immunoevasive strategies dir-
ectly impact on bothT and NK cells.
In the case of HLA-E:NKG2A, a favorable outcome of
an inhibitory interaction may appear paradoxical, but this
apparent paradox can be alleviated by considering, among
other factors taken into account in the original publication
[15], that NK cells cannot be simply switched on and off,
but need rheostat-like tuning [17]. Unlicensed by default,
they must undergo some kind of inhibitory receptor en-
gagement prior to arming [18]. Thus, HLA-E expression,
if too low, might itself promote tumor escape.
Whatever the instructive role of self HLA-E, one may
predict that harnessing a selected group of critical im-
mune checkpoints will simultaneously unleash a range
of immune effectors against cancer cells. Indeed, inter-
ference with a single function (antigen trimming in the
endoplasmic reticulum) of tumor cells induces a subtle
conformational change in MHC-I ligands that activates
both T and NK cells, leading to the concerted rejection
of a murine transplantable lymphoma that is otherwise
refractory to immune elimination [19]. Interestingly, the
mechanism of action involves triggering and relief of in-
hibition, in T and NK cells respectively, by a single lig-
and (Figure 2C). This model is particularly relevant to
the present issue, since tumor-rejecting T and NK cells
are both highly lytic, and rapidly (within a few hours)
convene at the tumor site ([19]; Figure 2D and E).
Although common ligands and the T/NK cell crosstalk
have been successfully exploited to reject murine tumors,
a question remains unanswered: will similar strategies re-
sult in significant clinical benefit in humans? So far there
are no startling reported results in clinical trials. T cell-
oriented (peptide) vaccination has indeed failed to meet
expectations [20]. One reason may be the intrinsic weak-
ness of a T cell-only anti-tumor response. On the other
hand, we are not aware of clinical trials deliberately aimed
at directly triggering both T and NK cells. Online search
(www.clinicaltrials.gov/) reveals that at least 7 ongoing
trials make use of IDO-specific inhibitors and vaccines. In
many cases, results are due shortly (Table 1). As to PGE2,
a major product of cyclooxygenase 2 (COX-2) activity [9],
anti-COX treatments are expected to impact not only on
cancer cell-autonomous events (e.g. promote/restore
apoptosis on the one hand, and quench angiogenesis and















Figure 2 Shared MHC-I ligands and tumor infiltration by T and NK cells. Schematic diagrams depicting tumor recognition by (A) a single
immune receptor (NKG2A) expressed by both T and NK cells, and (C) two distinct receptors: the TcR expressed by T cells and Ly-49 expressed by
NK cells, both specific for a single class of immune ligands (MHC-I molecules). Immunohistochemical stain (B) of NKG2A+ cells infiltrating (arrows)
a human colorectal carcinoma lesion. These are found in the context of CD8+ T cell infiltrates, whereas CD56+ cells were shown to be less than 2
per microscopic field, therefore marginally if at all contributing to NKG2A staining [16]. Counterstained with Hematoxylin. Fluorescent confocal
microscopy imaging of CD8+ T cells (D) and NK1.1+ cells (E), in red, infiltrating RMA murine lymphoma tumors expressing misfolded MHC class I
molecules. Counterstained with Hoechst 33342. Size bars: 40 μm in all panels.
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aware that immune restoration may come as an important
bonus of anti COX-2 clinical trials [9]. As of January 10,
2013, ongoing anti COX trials are 473 (www.clinicaltrials.
gov/; search string: COX inhibitors AND cancer). Al-
though online search does not readily identify anticipated
endpoints for T/NK cell assessment, the results of IDO
and PGE2 trials are eagerly awaited. More in general, find-
ing additional and common T/NK cell immune check-
points may pave the way for combination and/or low-dose
therapeutic schedules, possibly resulting in additive or
synergistic anti-tumor effects, and reduced toxicity.In conclusion, the quality of the immune infiltrate (in-
cluding the in situ interplay of immune ligands and
their receptors, particularly those shared by T and NK
cells) is in our opinion far more important than the
absolute NK cell count in the tumor. Appropriate
immunotherapeutic tactics are needed to overcome at
the same time poor gathering and poor killing. And
this applies to effectors of both the innate and the
adaptive immunity.Competing interests
The authors declare that they have no competing interests.
Table 1 Ongoing clinical trials with IDO inhibitors1
Trial number Treatment Tumor status Estimated
completion
Sponsor/Institution
NCT01219348 peptide2 NSCLC3 recruiting June 2012 Herlev Hospital, Copenhagen, Denmark
NCT01685255 INCB0243604 Ovarian cancer recruiting Nov 2015 Incyte Corporation, Wilmington, DE











recruiting undefined Lee Moffit Cancer Center, Tampa, FL and Virginia
Commonwealth University, Richmond, VA.
NCT01604889 INCB0243604 melanoma recruiting Feb 2015 Various locations, Incyte Corporation, Wilmington, DE




Mar 2013 Incyte Corporation, Wilmington, DE
1 Last searched online (www.clinicaltrials.gov) on January 10, 2013. Only trials involving patient treatment were selected. No observational trials are included.
Search string: “IDO”.
2 Vaccination scheme against an IDO epitope.
3 Non-Small Cell Lung Cancer.
4 Small molecule inhibiting IDO enzymatic activity.
5 A classical IDO inhibitor.
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